• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research

Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study
ConclusionIn STEMI patients undergoing PCI within 24 hr after thrombolytic therapy, bivalirudin was associated with a strong trend toward reduced bleeding complications as compared to heparin alone or heparin plus GPI.The optimal antithrombotic regiment for urgent PCI following thrombolytic therapy is currently unknown. Our study demonstrated that use of bivalirudin during PCI following thrombolytic therapy is associated with a trend toward reduced bleeding complications compared to heparin alone or heparin plus GPI. Large randomized trials of adjunctive anticoagulation during PCI in this complex post‐thrombolytic popula...
Source: Catheterization and Cardiovascular Interventions - April 18, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Jaya R. Mallidi, Peter Robinson, Paul F. Visintainer, Amir S. Lotfi, Scott Mulvey, Gregory R. Giugliano Tags: Coronary Artery Disease Source Type: research

Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta ‐analysis of studies
ConclusionCompared to UFH, Bivalirudin is associated with lower bleeding risk when used during CAS. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - August 15, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Jad Omran, Obai Abdullah, Mazen Abu ‐Fadel, William A Gray, Belal Firwana, Douglas E Drachman, Ehtisham Mahmud, Herebert D Aronow, Christopher J White, Ashraf S Al‐Dadah Tags: Peripheral Vascular Disease Source Type: research

Sex ‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - June 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick ‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

Sex‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - April 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: Results from the HORIZONS‐AMI trial
ConclusionIn patients undergoing transfemoral primary PCI for STEMI, VCD use was associated with significantly lower non‐CABG major bleeding irrespective of anticoagulation strategy. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - October 28, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Timothy A. Sanborn, Matthew I. Tomey, Roxana Mehran, Philippe Généreux, Bernhard Witzenbichler, Sorin J. Brener, Ajay J. Kirtane, Thomas C. McAndrew, Ran Kornowski, Dariusz Dudek, Eugenia Nikolsky, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Femoral vascular closure device use, bivalirudin anticoagulation and bleeding after primary angioplasty for STEMI: Results from the HORIZONS‐AMI trial
Conclusion: In patients undergoing transfemoral primary PCI for STEMI, VCD use was associated with significantly lower non‐CABG major bleeding irrespective of anticoagulation strategy. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - September 1, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Timothy A. Sanborn, Matthew I. Tomey, Roxana Mehran, Philippe Généreux, Bernhard Witzenbichler, Sorin J. Brener, Ajay J. Kirtane, Thomas C. McAndrew, Ran Kornowski, Dariusz Dudek, Eugenia Nikolsky, Gregg W. Stone Tags: Original Studie Source Type: research